Tilray (TLRY) shares surged 30% after President Trump hinted at reclassifying cannabis as a Schedule III drug. This move could benefit Tilray’s business by reducing restrictions and opening up new markets, potentially leading to sustainable profitability. Options data and Wall Street analysts suggest significant upside potential for Tilray stock in the future.

Read more at Barchart: Option Traders Are Pricing a Nearly 22% Move in Tilray Stock Before the End of 2025. Should You Buy, Sell, or Hold TLRY Here?